Insulet (PODD) Stock Analysis & AI Equity Report
Insulet (PODD) overview
Insulet (PODD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,708m and operating profit of USD 474m; the year-end share price was 284.24 USD and market capitalisation was USD 20,008m. Insulet is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Insulet's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Insulet
Insulet develops, manufactures and sells continuous insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System and Classic Omnipod. The company also produces pods for Amgen's Neulasta Onpro kit, a delivery system intended to help reduce infection risk after intensive chemotherapy.
Generate the Insulet report
Insulet is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Insulet and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Insulet
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.